Tedopi
Phase 2Small molecule
Tedopi is one of 63 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
199 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Beyfortus
BeiGenePhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Alecensa
RochePhase 3
Tarlatamab-Dznl
AmgenPhase 3
DATROWAY
Daiichi SankyoPhase 3
Ilaris
NovartisPhase 3
Lynparza
AstraZenecaPhase 3
Hycamtin
MMeitheal
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tedopi. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFondazione Ricerca Traslazionale